Sunfox Technologies Raises $7 Million to Scale Its Spandan Portable ECG Platform

Quick answer: Dehradun-based medtech company Sunfox Technologies has raised $7 million (about ₹67 crore) in a Series A round led by Ashish Kacholia, Lashit Sanghvi of Alchemy Capital and 3one4 Capital. The money will help scale Spandan, its portable, AI-enabled ECG platform, across India.

Sunfox Funding at a Glance

Detail	Information
Company	Sunfox Technologies (Dehradun, India)
Amount raised	$7 million (about ₹67 crore)
Round	Series A
Led by	Ashish Kacholia, Lashit Sanghvi (Alchemy Capital), 3one4 Capital
Flagship product	Spandan portable ECG platform
Devices deployed (company-reported)	About 60,000 across India
Villages reached (company-reported)	20,000+
Patients screened yearly (company-reported)	About 5 million via Spandan One
Previous round	₹15 crore (about $1.8 million), led by Venture Catalysts, 2024

What Is Sunfox Technologies?

Sunfox Technologies is an Indian medtech and R&D company building affordable, portable and AI-enabled healthcare devices, with a focus on cardiac care in places where specialist doctors are hard to reach. It is led by Founder and CEO Rajat Jain. Its co-founders include Arpit Jain, Saurabh Badola, Sabit Rawat and Nitin Chandola.

What Is Spandan?

Spandan is a portable electrocardiogram (ECG) device that records the heart’s electrical activity. Users and healthcare workers can capture an ECG with a smartphone, and the data can be shared with doctors remotely for review.

Spandan One is the software layer that supports remote review, case coordination and tele-ECG networks. Sunfox’s products are aimed at hospitals, clinics, telemedicine networks, public health programmes and home monitoring.

Why Does Portable ECG Matter in India?

Heart disease is a major health concern in India, and cardiologists are concentrated in big cities. A portable ECG lets a trained health worker in a village record a heart tracing and send it to a doctor, which can speed up detection of problems in people who would otherwise travel far for a test.

An ECG is a screening and diagnostic aid. It does not replace a doctor’s evaluation, and a normal reading does not rule out every heart condition.

How Will Sunfox Use the $7 Million?

According to the company announcement and media reports, the funds will be used to:

1. Expand Spandan across India
2. Grow the team
3. Invest in R&D
4. Build clinical evidence
5. Improve engineering
6. Develop new cardiac technologies

One report adds that the company is looking at regulatory clearances in the US and EU as part of its global ambitions. Treat this as a plan and not a confirmed approval.

What Investors Said

Lashit Sanghvi, co-founder of Alchemy Capital Management, said Sunfox has built a strong foundation in cardiac diagnostics with the potential to scale from India to global markets. CEO Rajat Jain said the round gives the team resources to take what it built in Dehradun to a much larger stage.

Why This Funding Round Matters

• It is Sunfox’s largest round so far. The new $7 million is roughly four times its 2024 round of about $1.8 million.
• Healthcare access is the theme. Investors are backing devices that bring basic diagnostics closer to patients.
• It tests a model beyond India. Sunfox now has capital to see whether its deployment approach can work in other markets.

Risks and Challenges

• Company-reported numbers. Device, village and patient figures come from Sunfox and have not been independently verified.
• Regulatory approvals. Entering the US and EU requires strict clearances that can take time.
• Clinical evidence. Medical devices need strong evidence of accuracy, which the company says it will invest in.
• Competition. Other portable and wearable ECG makers operate in India and abroad.
• Adoption. Success depends on training health workers and connecting devices to doctors.

Can You Invest in Sunfox?

Not through the stock market. Sunfox Technologies is a private company and is not listed on the NSE or BSE.

Frequently Asked Questions

How much did Sunfox Technologies raise?
$7 million (about ₹67 crore) in a Series A round.

Who led the round?
Ashish Kacholia, Lashit Sanghvi of Alchemy Capital, and 3one4 Capital.

What is Spandan?
A portable, AI-enabled ECG platform that records heart activity using a smartphone and enables remote diagnosis.

Where is Sunfox based?
Dehradun, Uttarakhand.

How many devices has Sunfox deployed?
About 60,000 across India, reaching more than 20,000 villages, according to the company.

Can a portable ECG replace a doctor visit?
No. It helps screening and remote review, but diagnosis and treatment need a qualified doctor.

Is Sunfox listed on the stock market?
No, it is a private company.

Final Thoughts

Sunfox’s $7 million raise reflects growing investor interest in affordable medtech that serves people outside big-city hospitals. The things to watch next are independent clinical evidence, regulatory clearances abroad and how well it expands its rural reach.

Medical disclaimer: This article is for general information only and is not medical advice. An ECG device does not replace a consultation with a qualified doctor. If you have chest pain, breathlessness or other symptoms of a heart problem, seek emergency medical care.

Financial disclaimer: This article is not investment advice. Details are based on company announcements and media reports as of October 7, 2026 and may change. Consult a SEBI-registered advisor before making any investment decision.

Sources: Inc42, Tech Observer, Tech Startups, nstartup, Indian Startup Times, Viestories, LocalSamosa.